Zytoreduktive Chirurgie und hypertherme intraperitoneale Chemoperfusion beim Ovarialkarzinom
Related Research units
Abstract
The achievement of macroscopically complete tumor resection in primary debulking surgery is the most important prognostic factor in advanced ovarian cancer. This results in a median survival benefit of >5 years. Systematic lymphadenectomy (LNE) is not indicated in advanced ovarian cancer with inconspicuous lymph nodes as it does not prolong overall survival and therefore should no longer be carried out above stage IIB with inconspicuous lymph nodes in imaging and by palpation. Primary cytoreductive surgery is the standard in advanced ovarian cancer. Neoadjuvant therapy is currently an option only if primary cytoreduction does not appear to be possible. For the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in primary debulking surgery a survival benefit has so far not been proven and therefore HIPEC is not recommended in this setting.
Bibliographical data
Translated title of the contribution | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer |
---|---|
Original language | German |
ISSN | 2731-6971 |
DOIs | |
Publication status | Published - 12.2022 |
Comment Deanary
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
PubMed | 36201013 |
---|